The Stamets Stack (Lion's Mane + Niacin + Psilocybin): What the Protocol Claims vs. Evidence

Regulatory notice: Psilocybin is a Schedule I controlled substance in the United States and is similarly restricted in most jurisdictions worldwide. Possession, cultivation, and distribution remain illegal under federal law regardless of state-level reform. This article reviews published claims about a patented protocol against the peer-reviewed evidence. Nothing here constitutes medical advice, a treatment recommendation, or encouragement to obtain or use a controlled substance.

Stamets Stack

0 peer-reviewed RCTs have tested the three-component combination

The Stamets Stack is described in US Patent US20180021326A1 and promoted by enthusiast sites, podcasters, and supplement vendors. This article works through the eight specific claims most often made about the protocol and weighs each against the published 2026 literature. Six are unsupported or untested in the combination. Two have partial mechanistic support. None have direct clinical-trial validation.

Patent US20180021326A1 (Stamets, 2019); Savides & Outhoff, Journal of Psychopharmacology, 2024; Nahlawi et al., Nature Cardiovascular Research, 2025

Patent

the protocol's source document is a patent application, not a clinical trial report (US20180021326A1, 2019)

8,703

participants in the largest naturalistic survey often cited as Stack evidence — co-authored by the patent holder (Rootman 2021)

5-HT2B

the receptor subtype where chronic activation links psilocybin frequency to theoretical cardiac risk (Rouaud 2024; Nahlawi 2025)

Patent US20180021326A1 (Stamets, 2019); Savides & Outhoff, Journal of Psychopharmacology, 2024; Nahlawi et al., Nature Cardiovascular Research, 2025

The Stamets Stack — sub-perceptual psilocybin, lion's mane mushroom extract, and flush niacin on a 5-days-on, 2-days-off schedule — has become one of the most discussed microdosing protocols on the internet. It originates from US Patent US20180021326A1, filed by mycologist Paul Stamets in 2019. Promotional content about the Stack appears across podcasts, supplement marketplaces, and enthusiast forums, and it tends to make a consistent set of specific claims about what the combination does and why.

This article works through those claims one at a time and asks a narrow question of each: what does the peer-reviewed literature say? The answers fall into three buckets. A few claims rest on real mechanistic findings from full-dose psilocybin research that have not been verified at microdosing concentrations. Several rest on plausible-but-untested biological logic that no one has run. And several rest on confidently-stated assertions for which no published data exists in either direction.

For the broader explainer of what the protocol is and where it comes from, see The Stamets Stack: Lion's Mane, Niacin, and Psilocybin Explained. This piece is the audit.

How This Audit Works

For each claim, three questions: What exactly is being asserted? What does the peer-reviewed literature say? And what is the honest verdict — supported, partially supported by extrapolation, plausible but untested, or unsupported?

A claim can be "true at the mechanistic level" while being "unsupported for the Stamets Stack specifically." Most claims about the protocol live in that distinction. Psilocybin does drive neuroplasticity. Lion's mane erinacines do induce nerve growth factor. Whether either effect occurs at sub-perceptual doses, whether the two compounds synergize, and whether flush niacin amplifies the result are all separate empirical questions, none of which has been answered in a controlled trial of this specific combination.

Claim 1: The Stack Combines Psilocybin's Neuroplasticity with Lion's Mane's NGF Stimulation for Synergy

This is the central mechanistic claim. The argument is that psilocybin promotes dendritic spine growth and BDNF signaling, lion's mane erinacines promote nerve growth factor production, and the two compounds together produce more brain plasticity than either alone.

The first half of the foundation is solid. Shao and colleagues, publishing in Neuron in 2021, demonstrated that a single dose of psilocybin produced approximately 10% higher dendritic spine density in the mouse frontal cortex within 24 hours, with effects persisting at least one month.^[1] A 2025 mechanism review by Sonda and colleagues in Trends in Pharmacological Sciences clarified that psilocybin's plasticity effect is mediated through direct TrkB receptor binding — TrkB is the receptor for BDNF, the brain's primary plasticity signal.^[2] The second half is also reasonable in isolation: erinacines from lion's mane mycelium induce NGF synthesis, and NGF acts on TrkA — a related receptor in the same Trk family.

What's missing is the bridge. No published study has co-administered psilocybin and lion's mane in any model — mouse, rat, cell line, or human — and measured a combined plasticity outcome. The mechanistic logic is coherent. The synergy is theoretical. The claim becomes "this combination should produce more plasticity than psilocybin alone," which is a testable hypothesis that has not been tested.

Claim 1

Synergy between psilocybin and lion's mane

The claim

“The Stack combines two complementary neuroplasticity mechanisms — psilocybin's BDNF/TrkB pathway and lion's mane's NGF/TrkA pathway — for greater plasticity than either alone.”

Patent rationale and enthusiast coverage.

What research shows

Partly True

Each mechanism is supported separately in full-dose or in-vitro models. No published study has co-administered psilocybin and lion's mane in any organism and measured a combined plasticity outcome.

The mechanistic logic is coherent. The empirical question — does the combination produce more plasticity than psilocybin alone — is open.

Shao et al., Neuron, 2021; Sonda et al., Trends Pharmacol Sci, 2025

Claim 2: Niacin Delivers Lion's Mane Erinacines to Peripheral Nerve Endings

This is the most distinctive element of the Stack and the least supported. The patent rationale is that flush niacin (nicotinic acid, 100–200 mg) causes peripheral vasodilation, which Stamets proposes helps deliver lion's mane bioactive compounds to nerve endings throughout the body, amplifying the protocol's effect on the peripheral and central nervous system.

There is no published pharmacokinetic study of this mechanism. A targeted PubMed search for the keywords "psilocybin + niacin + pharmacokinetic" returns zero results. The same combination of search terms returns zero results for "Stamets stack" and zero for "lion's mane + niacin + bioavailability." Flush niacin's vasodilatory effect is real. Whether vasodilation meaningfully increases erinacines bioavailability at peripheral nerve terminals, and whether this affects the protocol's central nervous system outcomes, has not been studied in any published peer-reviewed research.

This is not a criticism of niacin as a supplement. It is a clarification that the specific role niacin is asked to play in the Stack — pharmacokinetic enhancer of lion's mane delivery — is a hypothesis articulated in the patent and not yet examined in the literature. The honest verdict is "plausible but untested."

Claim 3: Sub-Perceptual Microdoses Produce BDNF and Plasticity Effects Like Full Doses

This claim is the load-bearing premise for the entire microdosing-with-the-Stack rationale. If sub-perceptual doses produce the same neurochemical effects as full doses, then microdosing could deliver therapeutic benefit without the perceptual disruption. If they don't, the mechanistic case collapses.

The 2025 Kinderlehrer review in Neuropsychiatric Disease and Treatment is direct about this gap: most of the mechanistic data showing BDNF increases, neuroplasticity, and TrkB binding comes from full-dose or high-dose models, and whether sub-perceptual concentrations produce the same effects is an open question.^[3] The 2025 Sonda mechanism review reaches the same conclusion: dose-response relationships for psilocybin's plasticity effects are characterized at therapeutic doses and remain extrapolation at microdosing concentrations.^[2]

This is not a "the Stack doesn't work" finding. It is a "the mechanistic case for sub-perceptual plasticity hasn't been completed yet" finding. The Stack assumes the answer is yes. The literature has not yet shown that it is.

Claim 4: Microdosing Reliably Improves Mood, Anxiety, and Depression

The naturalistic evidence for this claim is the most commonly cited support for the Stamets Stack. The Rootman 2021 study, published in Scientific Reports with N = 8,703 participants, found that microdosers reported lower depression and anxiety scores than non-microdosers, along with higher wellbeing measures.^[4] The 2024 Savides and Outhoff review in the Journal of Psychopharmacology summarizes the broader naturalistic literature as consistently positive.^[5]

The blinded literature tells a more nuanced story. The Szigeti 2021 self-blinding citizen science study in eLife, which enrolled ~191 participants and tested them against their own self-administered placebo, found that improvements were strongly predicted by what participants thought they had taken rather than what they had taken — pointing toward expectancy as a key driver.^[7] Polito and Liknaitzky's 2024 rapid review of 19 placebo-controlled microdosing studies in the Journal of Psychopharmacology reached a more cautious conclusion: it found evidence of real neurobiological, physiological, and subjective effects relative to placebo, and explicitly argued that claims calling microdosing "predominantly a placebo" are "premature and possibly wrong," citing eight methodological gaps in the evidence.^[6] Their conclusion: "it is not yet possible to determine whether microdosing is a placebo." Polito & Liknaitzky's message is that the question is open — not that it is settled in favor of expectancy.

Claim 4

Mood and depression benefits

The claim

“Microdosing reliably improves mood, reduces depression, and lowers anxiety — supported by surveys of thousands of users.”

Naturalistic surveys; Rootman 2021 most-cited.

What research shows

Overstated

Naturalistic surveys (open-label, self-selected) consistently show positive results. Blinded controlled trials show smaller or no effects. The Szigeti 2021 self-blinding study found outcomes tracked what participants believed they took, not what they actually took — suggesting expectancy as a driver. Polito & Liknaitzky 2024 reviewed 19 placebo-controlled studies and concluded that calling microdosing 'predominantly a placebo' is premature — the question of pharmacological vs. expectancy effects remains genuinely open.

The Szigeti self-blinding result points toward expectancy. Polito & Liknaitzky 2024 explicitly caution against concluding the question is settled, citing 8 methodological gaps. Both facts are needed for an accurate characterization.

Szigeti et al., eLife, 2021; Polito & Liknaitzky, J Psychopharmacol, 2024; Rootman et al., Sci Rep, 2021

The methodological issue underlying both naturalistic studies is self-selection. People who try a microdosing protocol and feel better are dramatically more likely to enroll in a survey than people who try it and feel nothing. This biases the sampled population in a direction that even careful survey design cannot fully correct.

Claim 5: The Rootman 2021 Survey Is Independent Evidence for the Stamets Protocol

The Rootman 2021 study is the single most-cited piece of evidence in promotional content about the Stamets Stack. Reviews of the Stack consistently lead with it.

Paul Stamets is a co-author. The conflict of interest is disclosed in the paper itself but rarely disclosed in promotional content that cites it. This is not an accusation of misconduct — the author list is public and the journal followed standard practice — but it is a material fact that should accompany every citation. The patent holder participating in the naturalistic survey most often used to validate his own patented protocol is exactly the conflict that conflict-of-interest disclosures exist to flag.

A consequence: when promotional content describes Rootman 2021 as "independent third-party research supporting the Stack," that description is inaccurate. The study is naturalistic survey research that includes the protocol's developer as a co-author. That doesn't make the findings false. It does make them not-independent.

Claim 6: The 5-Days-On, 2-Days-Off Schedule Is Safer or Equivalent to Other Protocols

The Fadiman protocol — the most-studied microdosing schedule — is 1 day on, 2 days off. The Stack's schedule is 5 days on, 2 days off. The two schedules are different in a specific way that matters for the leading long-term safety concern.

Chronic activation of the 5-HT2B serotonin receptor in cardiac tissue is associated with valvular fibrosis. The diet drug fenfluramine was withdrawn from the market for this reason. The dopamine agonist cabergoline has produced valvulopathy through the same mechanism. Psilocybin and its active metabolite psilocin bind 5-HT2B alongside the desired 5-HT2A site.

The 2024 Rouaud, Calder, and Hasler review in the Journal of Psychopharmacology evaluated the structural and pharmacological similarities between psilocybin (and LSD) and drugs known to cause cardiac fibrosis — including methysergide, pergolide, fenfluramine, and MDMA — through their shared 5-HT2B receptor activity.^[8] The review concluded that chronic microdosing with psilocybin or LSD plausibly raises the risk of cardiac fibrosis and valvulopathy through the same 5-HT2B mechanism, and recommended cardiac monitoring in future microdosing safety studies. The 2025 Nahlawi review in Nature Cardiovascular Research confirmed chronic 5-HT2B activation is the primary theoretical long-term cardiac concern for any psychedelic used in a frequent low-dose pattern and recommended cardiac monitoring for such users.^[9] The 2023 Wsól review in Pharmacological Reports reached the same conclusion from a broader cardiovascular-safety frame.^[10]

Cardiac safety

Moderate

The 5-days-on schedule is not the same risk profile as 1-on-2-off

Concern

The Stamets Stack delivers five days of cumulative 5-HT2B receptor activation per week. The Fadiman protocol delivers two-to-three. Chronic 5-HT2B activation is the mechanism by which fenfluramine and cabergoline produce cardiac valvulopathy. Psilocybin and LSD share structural similarities with these withdrawn drugs and bind 5-HT2B, making the cardiac risk plausible for frequent long-term microdosing schedules — a concern three independent reviews in 2023–2025 flag as warranting cardiac monitoring.

What the research says

No confirmed cases of microdosing-related valvulopathy have appeared in the published literature as of 2026. The absence of cases is partly because no long-term cardiac monitoring studies of microdosers have been conducted. Three independent recent reviews recommend cardiac monitoring for users on frequent extended schedules.

Particularly relevant for: Anyone using the Stamets Stack on its 5/2 schedule for more than a few months, particularly with personal or family history of valvular disease.

What to do

If using any frequent microdosing schedule, baseline and follow-up echocardiography is the monitoring tool the cardiac safety literature recommends.

Rouaud et al., J Psychopharmacol, 2024; Nahlawi et al., Nature Cardiovasc Res, 2025; Wsól, Pharmacol Rep, 2023

The honest verdict on Claim 6: the Stack's schedule is more, not less, exposed to the leading theoretical long-term cardiac concern than the Fadiman schedule. Whether that translates to clinically meaningful valvulopathy risk is unknown and unstudied, but "more cumulative activation" is the correct direction.

Claim 7: The 5/2 Schedule Prevents Tolerance Build-Up

The patent rationale for the two rest days is tolerance management — psilocybin's 5-HT2A receptor downregulates with repeated activation, and the two off-days are intended to allow receptor recovery.

The pharmacology of 5-HT2A tolerance is real. Repeated full-dose psilocybin produces measurable tolerance within days. Whether two rest days per week meaningfully resets receptor sensitivity at sub-perceptual concentrations has not been measured. The patent describes the 5/2 schedule as designed to balance accumulation and recovery; the underlying receptor-recovery kinetics at microdose-relevant occupancies have not been published.

This is another case where the rationale is plausible biology that no one has tested. The Stack assumes the answer; the literature has not produced it.

Claim 8: The Patent's Title Implies Inflammatory and Neurogenerative Disease Treatment

US Patent US20180021326A1 is titled "Psilocybin mushroom combination for the treatment of inflammatory diseases." Some promotional content treats the patent title as endorsement of the protocol as a treatment.

Patent titles are written by the inventor and describe the intended use claimed for the invention. They are not regulatory approvals, clinical trial outcomes, or peer-reviewed indications. The US Patent and Trademark Office grants patents based on novelty, non-obviousness, and a plausible mechanism. Patents do not require evidence of efficacy in humans.

The verdict is straightforward. The patent's existence is a fact. The patent's title is a fact. Neither is evidence that the combination treats inflammatory or neurogenerative disease in humans. No FDA, EMA, or comparable regulatory body has approved the combination for any therapeutic indication.

Where the Evidence Actually Sits

The above eight claims, taken together, describe a protocol with thoughtful mechanistic rationale and essentially no clinical-trial evidence as a combination. The strongest evidence runs on the individual components at full doses, in animal models, or in self-report surveys with significant methodological limitations.

Stamets Stack as a combination

1. Cell and receptor studies — components individuallycompleted

   Psilocybin TrkB binding (Sonda 2025); lion's mane erinacines NGF induction (multiple, full-dose mycelium).

2. Animal studies — components individuallycompleted

   Psilocybin dendritic spine density in mice (Shao 2021, ~10% increase); lion's mane neuroprotection in rodent models.

3. Case reports — combined protocolmissing

   No published case reports of clinical outcomes from the Stack as a three-component combination.

4. Small trials — combined protocolmissing

   Self-blinding studies (Szigeti 2021) and blinded microdosing trials exist for psilocybin alone but not for the Stack combination.

5. Large RCT — combined protocolmissing

   No randomized controlled trial of psilocybin + lion's mane + niacin has been published or registered as of June 2026.

6. Meta-analysis — combined protocolmissing

   Meta-analyses cover microdosing broadly (Savides 2024; Polito & Liknaitzky 2024) but none can include the Stack as a discrete intervention because the constituent trials do not exist.

The Stamets Stack as a combination has not progressed past animal and cell evidence for its individual components. Every level of human evidence — case reports, small trials, large RCTs, and meta-analyses — is empty for the three-component protocol. Claims about the Stack's clinical effect are extrapolations across this gap.

Shao 2021; Sonda 2025; Szigeti 2021; Savides 2024; Polito & Liknaitzky 2024

The Honest Bottom Line

The Stamets Stack is a hypothesis. It is a thoughtful one, grounded in real mechanisms, with internal logic that holds together. The patent describes a plausible biological story. The individual components have substantial separate research support. The 5/2 schedule is a defensible engineering choice for tolerance management if the underlying receptor-recovery kinetics turn out to favor it.

What the protocol is not, as of 2026, is a clinically validated treatment. The published literature does not contain a randomized controlled trial of the combination. The naturalistic survey evidence most often cited as support is methodologically self-selected and includes the patent holder as a co-author. The strongest blinded data is mixed in instructive ways. Szigeti 2021 found that outcomes tracked what participants believed they had taken, not what they actually received — a result consistent with expectancy driving the signal. Polito and Liknaitzky's 2024 rapid review of 19 placebo-controlled studies, however, found real neurobiological and subjective effects relative to placebo and explicitly cautioned that calling microdosing "predominantly a placebo" is premature — the question remains open. Both findings are needed for an accurate bottom line: the expectancy explanation has meaningful support (Szigeti 2021), and it has meaningful challenge (Polito & Liknaitzky 2024).

For a more detailed analysis of where the mechanistic case currently sits, see How the Stamets Stack Theoretically Enhances Neuroplasticity. For comparison with other scheduling approaches, see Microdosing Protocols Compared: Fadiman vs. Stamets vs. Every Other Day. For a focused look at the cardiac concern, see Microdosing and Heart Health: The 5-HT2B Valvulopathy Concern.

The honest summary for anyone evaluating the Stamets Stack: take its claims seriously as a research program worth pursuing. Do not take them as established findings already produced.

The Bottom Line

This audit walked through the eight claims most commonly made about the Stamets Stack and tested each against the 2026 peer-reviewed literature. None of the claims are supported by a randomized controlled trial of the three-component combination — no such trial exists. Two claims (psilocybin neuroplasticity, lion's mane NGF stimulation) have real mechanistic support at full doses or in isolated systems but have not been validated at sub-perceptual concentrations or in combination. The niacin distribution claim has no published pharmacokinetic study supporting it. The mood-benefit claim is supported by naturalistic surveys but substantially attenuated by blinded trials; the Szigeti 2021 self-blinding study points to expectancy as a key driver of the survey-to-trial gap, while Polito & Liknaitzky 2024 caution that declaring microdosing predominantly a placebo is premature — the pharmacological vs. expectancy question remains open. The schedule-safety claim runs the wrong direction: the 5/2 schedule produces more cumulative 5-HT2B activation than less-frequent protocols, and chronic 5-HT2B activation is the leading theoretical long-term cardiac concern. The most defensible characterization is that the Stamets Stack is a coherent hypothesis in need of testing, not a validated treatment.

Frequently Asked Questions

Has the Stamets Stack been tested in a clinical trial?

No. As of June 2026, no peer-reviewed randomized controlled trial has tested the three-component combination of psilocybin, lion's mane, and niacin. A PubMed search for "Stamets stack" returns one result — Rootman 2021, a naturalistic survey, not a trial of the combination. The individual components have been studied separately and at different doses, but the Stack as a discrete intervention has not been clinically validated.

Is the Rootman 2021 study independent evidence for the Stack?

Paul Stamets — the patent holder for the protocol — is a co-author on Rootman 2021. The conflict is disclosed in the paper itself but is rarely mentioned in promotional content. The study is a naturalistic survey (open-label, self-reported, self-selected sample) with N = 8,703. The findings are positive for microdosing generally, but the study cannot be characterized as independent third-party evidence for the Stack.

Does niacin actually help deliver lion's mane to the brain in the Stack?

The claim — that flush niacin's peripheral vasodilation enhances lion's mane erinacines bioavailability at peripheral nerve terminals — is articulated in US Patent US20180021326A1 as a theoretical mechanism. No published pharmacokinetic study has measured whether flush niacin meaningfully increases erinacines distribution to nerve endings, and no study has shown that niacin's addition changes the central nervous system effects of the lion's mane component. The niacin role in the Stack is a hypothesis, not a measured effect.

Do sub-perceptual psilocybin doses produce the same BDNF and neuroplasticity effects as full doses?

This is an open question in the literature. The 2025 Kinderlehrer review and the 2025 Sonda mechanism review both conclude that most of the BDNF, dendritic spine, and TrkB-binding data come from full-dose studies, and whether sub-perceptual concentrations produce the same effects is not yet established. The Stack's mechanistic rationale assumes the answer is yes; the published evidence does not yet confirm it.

Is the 5-days-on, 2-days-off schedule safer than the Fadiman protocol?

No. The Stack's schedule delivers more cumulative weekly 5-HT2B serotonin receptor activation than the Fadiman 1-on-2-off schedule. Chronic 5-HT2B activation is the mechanism by which fenfluramine and cabergoline produced cardiac valvulopathy. The 2024 Rouaud review in the Journal of Psychopharmacology evaluated the structural and pharmacological similarities between psilocybin and these withdrawn cardiotoxic drugs, concluded that chronic microdosing plausibly raises cardiac fibrosis risk through 5-HT2B activity, and recommended cardiac monitoring in future safety studies. The 2025 Nahlawi review in Nature Cardiovascular Research and the 2023 Wsól review in Pharmacological Reports reach the same conclusion. No confirmed cases of microdosing valvulopathy have been published, but no long-term cardiac monitoring studies have been done either.

Should I take the Stamets Stack?

This article is research analysis, not medical advice. Psilocybin is illegal in most jurisdictions. The evidence base for the Stack as a combination is essentially absent. The cardiac safety concern for frequent microdosing schedules is real and unquantified. Anyone considering the protocol should consult a physician, understand the legal risk in their jurisdiction, and recognize that confident claims about the protocol's benefits are extrapolations beyond what the peer-reviewed literature currently supports.

Sources & References

1. 1RTHM-01434·Shao, Ling-Xiao et al. (2021). “Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo..” Neuron.Study breakdown →PubMed →↩
2. 2RTHM-02182·Sonda, Sonia et al. (2025). “Emerging mechanisms of psilocybin-induced neuroplasticity..” Trends in pharmacological sciences.Study breakdown →PubMed →↩
3. 3RTHM-00929·Kinderlehrer, Daniel A (2025). “Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity..” Neuropsychiatric disease and treatment.Study breakdown →PubMed →↩
4. 4RTHM-00715·Rootman, Joseph M et al. (2021). “Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers..” Scientific reports.Study breakdown →PubMed →↩
5. 5RTHM-00905·Savides, Isabella A et al. (2024). “Less is more? A review of psilocybin microdosing..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
6. 6RTHM-00900·Polito, Vince et al. (2024). “Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
7. 7RTHM-01441·Szigeti, Balázs et al. (2021). “Self-blinding citizen science to explore psychedelic microdosing..” eLife.Study breakdown →PubMed →↩
8. 8RTHM-00903·Rouaud, Antonin et al. (2024). “Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
9. 9RTHM-02156·Nahlawi, Acile et al. (2025). “Cardiovascular effects and safety of classic psychedelics..” Nature cardiovascular research.Study breakdown →PubMed →↩
10. 10RTHM-01822·Wsół, Agnieszka (2023). “Cardiovascular safety of psychedelic medicine: current status and future directions..” Pharmacological reports : PR.Study breakdown →PubMed →↩